AIM: £3.75 (+0.05) | Nasdaq: $23.61 (-0.26)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
CNBC Squawk Box
CEO Christian Hogg discusses surufatinib NDA submission
Watch Interview
SANET-ep Results
Audio Webcast on Surufatinib Trial Results
Watch presentation
FY2019 Interim Results
Announcement and Presentation webcast
View Event Details
Fruquintinib in JAMA
Full text of FRESCO colorectal cancer trial published
Read Abstract
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Group
|
11 Nov 2019
Chi-Med to Attend Upcoming Investor and Industry Conferences
Innovation Platform
|
11 Nov 2019
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
Innovation Platform
|
17 Oct 2019
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
Innovation Platform
|
10 Oct 2019
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
Innovation Platform
|
4 Oct 2019
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
Current Share Price
London AIM:HCM
£3.75
+0.05 | 21 Nov 2019 | 08:48
Nasdaq AIM:HCM
US$23.61
-0.26 | 21 Nov 2019 | 16:00
Note: 1 Nasdaq share = 5 AIM shares
Latest Presentations
18 Nov 2019
Corporate presentation
13 Nov 2019
Deutsche Bank ADR Virtual Investor Conference (dbVIC)
30 Sep 2019
Post-ESMO Surufatinib Update
29 Sep 2019
ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs
Latest Reports
Interim Report 2019
EN
Annual Report 2018 (with Form 20-F)
EN
Interim Report 2018
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Deutsche Bank
Edison
HSBC
Macquarie
Panmure Gordon
Trinity Delta
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More